Skoči na glavni sadržaj

Pregledni rad

Systemic therapy of early breast cancer

Robert Šeparović orcid id orcid.org/0000-0002-4002-2699 ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Tajana Silovski orcid id orcid.org/0000-0002-4699-5432 ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Robert Zorica ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Mirjana Pavlović orcid id orcid.org/0000-0002-9633-064X ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ljubica Vazdar ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Vesna Pavlica ; Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia


Puni tekst: engleski pdf 177 Kb

str. 41-50

preuzimanja: 215

citiraj


Sažetak

Breast cancer is the most common cancer in women. Early breast cancer is potentially curable disease. Systemic adjuvant therapy is created to treat micrometastatic disease or destroy breast cancer cells that have spread from the breast and regional lymph nodes, but have not yet formed visible distant metastases. Systemic adjuvant therapy is based on chemotherapy
with or without targeted therapy, and endocrine therapy, sometimes in combination with adjuvant irradiation, usually is conducted after surgery. The aim of adjuvant therapy is to decrease recurrence rate and extension of overall survival

Ključne riječi

breast cancer; micrometastasis; adjuvant chemotherapy; biological therapy; survival rate

Hrčak ID:

199077

URI

https://hrcak.srce.hr/199077

Datum izdavanja:

29.12.2014.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.447 *